AgeX Therapeutics has issued two types of preferred stocks, Series A and B, to Juvenescence Ltd as part of a deal to cancel $36 million in debt encompassing certain loans and origination fees. With this exchange, AgeX meets the NYSE American's listing requirements and has avoided a potential delisting. As of now, the NYSE American has approved the listing of 36,939,190 shares of AgeX common stock into which the preferred stock can be converted.